Spyre Therapeutics
At Spyre, our aim is to develop novel therapies for gastrointestinal and rheumatic diseases built upon three validated approaches:
- Engineering novel antibodies against validated targets
- Incorporating the YTE-modification to prolong drug activity and reduce administration frequency, with potential for improved clinical outcomes through dose optimization and higher drug exposures
- Developing rational drug combinations in simple high-concentration coformulations that may address distinct disease drivers and lead to superior efficacy and convenience
Together, if successful, we believe our approach will deliver new therapies to patients that have best-in-indication efficacy and convenience and represent a significant improvement over today’s standard of care
221 Crescent Street, Suite 105
Waltham, MA 02453
Waltham, MA 02453
NEWS
It’s been a busy week for biopharma companies to name a chief executive officer. Over the past week, multiple companies have selected individuals to hold the top spots and guide the growth strategies of their companies.
Aeglea BioTherapeutics announced new repeat dose data from its Phase I/II trial of AEB1102 (pegzilarginase) in patients with Arginase 1 Deficiency.
BioSpace is pleased to present its NextGen Bio “Class of 2016.” This list contains 20 life science companies that launched no earlier than 2013 and are headquartered in the United States.
JOBS
IN THE PRESS